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Recent studies demonstrate that presenilins (PSs) and signal peptide peptidase (SPP) are members of a
novel protease family of integral membrane proteins that may utilize a catalytic mechanism similar to classic
aspartic proteases such as pepsin, renin and cathepsin D. The deﬁning features of the PSs and SPP are their
ability to cleave substrate polypeptides within a transmembrane region, the presence of two active site
aspartate residues in adjacent membrane-spanning regions and a conserved PAL motif near their COOH-
terminus. PSs appear to be the catalytic subunit of multiprotein complexes that possess c-secretase activity.
Because this activity generates the amyloid b peptide (Ab) deposited in the brain of patients with Alzheimer’s
disease (AD), PSs are considered therapeutic targets in AD. In contrast to PSs that are not active unless part
of a larger complex, SPP does not appear to require protein co-factors. Because of its requirement for
hepatitis C virus maturation and a possible immune modulatory role, SPP is also considered a potential
therapeutic target. Four additional PS/SPP homologs have been identiﬁed in humans; yet, their functions
have not been elucidated. Herein, we will review the recent advances in our understanding of the PS/SPP
family of proteases as well as discuss aspects of intramembrane cleavage that are not well understood.
INTRODUCTION
In order to more accurately reflect their catalytic activities,
proteases have been referred to as peptide peptidohydrolases.
This terminology reflects the catalytic mechanism in which a
water molecule plays an essential role in cleaving a peptide
bond. Until recently, all characterized ‘classic’ proteases had
been shown to have an active site domain located in the
aqueous environment of the cytoplasmic, lumenal or extra-
cellular space. Thus, cleavage of peptide bonds buried within
the hydrophobic interior of a cellular membrane was postulated
to require either breakdown of the membrane or transport of
substrate out of the lipid bilayer to an aqueous environment.
The recent identification of several families of membrane
proteases that seem capable of cleaving peptide bonds present
within the lipid bilayer has dramatically changed the concept of
how transmembrane regions of proteins may be cleaved (1,2).
Three families of proteases that carry out ‘intramembrane
proteolysis’ are recognized (1,2). Though exact catalytic
mechanisms remain elusive, there is evidence that the active
site of these proteases could lie within the plane of the lipid
bilayer, and that proteases within each family may utilize
conserved catalytic mechanisms analogous to those found in
classic proteases. The first family, whose prototypic member is
the human site-two protease (S2P) that cleaves and activates
sterol regulatory element binding proteins (SREBPs), appears
to be a group of metalloproteases (3). The second family, the
rhomboids, whose prototypic member Drosophila Rhomboid-1
cleaves and liberates several EGF ligands, appears to be a
group of serine proteases (4). A third family, whose prototypic
members are the presenilins (PSs) involved in cleavage of the
amyloid b protein precursor (APP) and Notch, appears to be a
group of aspartic proteases (5,6). Collectively these proteases
have been referred to as intramembrane-cleaving proteases
(I-CLiPs). For several reasons a great deal of attention has
focused on the aspartic I-CLiP family. First, the prototypic
members of this family, the human PSs, are therapeutic targets in
Alzheimer’s disease (AD). Second, a new member of this family,
signal peptide peptidase (SPP), was recently identified and
shown unequivocally to possess proteolytic activity and have
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biological functions that may also make it a therapeutic target.
Herein, we will discuss these recent advances with respect to the
presenilin/signal peptide peptidase family of I-CLiPs.
PRESENILINS
PSs are integral membrane proteins with 6–8 predicted
transmembrane regions. They were first identified through
genetic linkage analysis in families with early onset autosomal
dominant forms of AD (7,8). PSs are synthesized as 50 kDa
proteins, but are rapidly endoproteolyzed into NH2- (30 kDa)
and COOH- (20 kDa) terminal fragments, which remain
associated along with other proteins in a high molecular weight
complex (9,10). To date, 100 AD-linked mutations have been
found in presenilin 1 (PS1) and several more in presenilin 2
(PS2) (11). Almost concurrent with the identification of
mutations in PSs as genetic causes of AD, there was some
evidence linking PSs to the proteolytic activity referred to as
g-secretase (12). This activity is involved in the production of
the amyloid b peptide (Ab) from its precursor, APP. Following
cleavage of APP by b-secretase, g-secretase cleaves the
membrane bound COOH-terminal APP fragment within its
transmembrane region generating both the 4 kDa Ab peptide
and a cognate COOH-terminal cleavage product. The cut in the
membrane is heterogeneous with multiple Ab species produced
ranging in length from 32–42 amino acids (13). The most
prevalent form of Ab is one of 40 amino acid residues (Ab40);
under typical circumstances Ab40 represents >50% of the Ab
secreted from a cell. However, an Ab species of 42 amino acids
(Ab42) appears to play a causal role in AD pathogenesis. To
date, all AD-linked mutations in PS1 and PS2 have been
shown to increase the relative production of Ab42 even in
asymptomatic carriers, and expression of a mutant PS gene in
transgenic mice overexpressing human APP, accelerated
accumulation and aggregation of Ab in the brain (12,14).
Despite the evidence that mutations in PSs altered the
g-secretase activity that generated Ab, no one readily endorsed
the idea that PSs were g-secretases. PSs did not bear homology
to classic proteases; thus, it was proposed that PSs influenced
g-secretase activity indirectly. Over the past few years, genetic
and biochemical evidence has emerged demonstrating that PSs
are in fact g-secretases. Knockout studies of PS1 and PS2
demonstrated an essential role of these proteins in g-secretase
cleavage. PS1 knockout decreased g-secretase activity by
80%, a PS2 knockout had little or no effect, and a combined
PS1 and PS2 knockout abolished g-secretase activity (15–18).
Biochemical studies showed that PS1 co-fractionates with
g-secretase activity in a high molecular weight complex and
this in vitro activity could be recovered in the pellet after
immunoprecipitation with antibodies to PS1 (19). Significantly,
mutation of conserved aspartate residues (D257 and D385 in
PS1, and D263 and D366 in PS2) present in two adjacent
transmembrane regions produced dominant negative forms of
PS that inhibited g-secretase activity in cells (5). These studies
together with inhibitor studies suggested that PSs might be
aspartic type proteases (20). Finally, inhibitors of g-secretase
activity have been shown to directly target both PS1 and PS2
(21–24). Moreover, given that two groups had specifically
designed their inhibitors to be transition state analogs of
aspartic proteases (21,22), it certainly appears that despite the
lack of demonstrable homology to known aspartic proteases,
PS may be just that.
Recent insight into the other components of the high
molecular weight complex that contains g-secretase activity
and PSs, now offers a more complete picture of g-secretase.
Three additional proteins are required for g-secretase activity in
cells. Nicastrin (Nct, APH-2) is a 130 kDa type I membrane
protein that was originally purified from the complex (25). Two
additional proteins, APH-1, another integral membrane protein
of 30 kDa with multiple transmembrane regions, and PEN-2,
a small hairpin like protein of 12 kDa, were initially isolated
from genetic screens in Caenorhabditis elegans (26). Together
with a PS, the three components appear to comprise a minimal
functional g-secretase complex (27–29). Although the precise
function of each subunit is not yet definitively established, it
appears that PSs are the catalytic component, and that Nct,
APH-1 and PEN-2 play various roles in the stabilization and
maturation of the complex. It is also possible that these
‘accessory’ proteins are involved in substrate presentation.
The biological activities of g-secretase and PSs have been
extensively reviewed (2,30). Although some activities of PSs
are distinct from their protease activity (e.g. stabilization of
b-catenin), many are not. g-Secretase activity regulates Notch
and APP signaling by promoting the release of the cytoplasmic
tail from a membrane bound fragment of each precursor. It is
not clear whether the release of small peptides, such as Ab, into
the exoplasmic space has any demonstrable physiologic
function. It is also not clear whether g-secretase cleavage of
substrates other then Notch and APP has some physiologic
functions. It is possible that g-secretase cleavage of certain
substrates may simply be a mechanism to breakdown these
proteins. A current list of g-secretase substrates, cleavage
products and putative functions are listed in Table 1.
SIGNAL PEPTIDE PEPTIDASE
The second, more recently identified member of the aspartic
I-CLiP family is the SPP of higher eukaryotes (31). Typical for
an aspartic I-CLiP, SPP is a predicted multispanning membrane
protein containing two putative active site aspartates that
are located in the centre of adjacent transmembrane regions.
The latter feature is consistent with the observed cleavage of
substrate peptides in the centre of their membrane-spanning
portion. In addition, SPP contains two endoglycosidase
H-sensitive N-glycans and an ER retrieval signal, KKxx,
ascribing SPP a function in the endoplasmic reticulum (ER) (31).
The role of SPP in cell function is poorly understood. The
SPP substrates identified to date, represent a variety of signal
peptides and a viral protein (Table 2) (31–34). They do not
unequivocally demonstrate to a role of SPP either in the
degradation of signal peptides that may otherwise accumulate
in the ER membrane, or in the activation of signaling or
regulatory molecules, or both. Potential orthologs of SPP are
found in the genomes of animals and plants but not fungi and
bacteria (31,35). Therefore, the prime role of SPP may not
necessarily be the clearance of membranes from signal
peptides, which are produced in all organisms, and a more
basic mechanism may exist to fulfil that function. We may thus
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speculate that SPP, in analogy to other I-CLiPs, may promote
the liberation of bioactive peptides or proteins from the ER
membrane. The generation of HLA-E epitopes in humans
represents the first example of such an SPP-dependent
production of a bioactive peptide, which in this case functions
as a reporter. HLA-E epitopes that play a key role in immune
surveillance, are produced from the signal sequences of the
antigen presenting MHC class I molecules in a process that
depends on SPP (36). The epitopes are eventually presented at
the cell surface of most of our cells, where they are recognized
by the natural killer (NK) cells of the immune system.
Presentation of these signal peptide-derived epitopes is an
indirect indication that the probed cell is healthy and had
properly synthesized MHC class I molecules. If such epitope
presentation is defective or otherwise disturbed, e.g. due to a
virus infection or transformation to a tumor cell, these impaired
cells are thought to be recognized and eliminated by the NK
cells (37).
The substrate spectrum of SPP may not be restricted to
classic signal peptides, which typically are short, NH2-terminal
extensions of a precursor protein. The finding that SPP is
exploited by the hepatitis C virus (HCV) for the processing of
the viral core protein, implies that the protease may also
catalyse intramembrane cleavage of membrane anchored
proteins, similar to other I-CLiPs (34). During biosynthesis
of viral proteins in HCV infected cells, the immature HCV core
protein is transiently anchored in the ER membrane via a
COOH-terminal, signal peptide-like sequence. Intramembrane
proteolysis by SPP promotes the final processing of core
protein and its release from the ER membrane into the cytosol.
Likewise, we may speculate that proteins anchored in the ER
membrane by a signal peptide-like sequence, may be liberated
from the ER membrane and activated upon cleavage by SPP.
PRESENILIN AND SPP: SIMILARITIES AND
DIFFERENCES
Despite limited areas of direct sequence homology, PSs and
SPP are membrane proteins whose sequences can be aligned
almost throughout their entire lengths (31,35). PSs and SPP
share identical active site motifs, YD and LGLGD (Table 3). In
addition, they contain a third conserved region, PAL, which
seems characteristic for the entire aspartic I-CLiP family.
Moreover, the YD and LGLGD motifs, which contain the
catalytic aspartate residues, are unusual in that they are present
within predicted adjacent and opposing transmembrane
regions. The similarities between PSs and SPP, particularly
the identity of the active site motifs, point to a common
catalytic mechanism. Indeed, a series of protease inhibitors
including aspartic protease transition state analogues, targeted
to the active site of SPP and PSs, inhibited both activities (38).
Because both enzymes are potential targets for therapeutic
intervention—PSs for the treatment of AD and SPP for the anti
HCV therapy—it will be a challenging task for the future to
define compounds and conditions for the selective inhibition of
either protease.
Another common feature, and one that is typical of many
I-CLiPs, is that both PS and SPP activity appear to require prior
cleavage of the substrate to remove its ectodomain. SPP
substrates are first cleaved by signal peptidase (33), whereas
PS/g-secretase substrates are first cleaved by shedding
proteases (e.g. ADAM family members and b-secretase)
(39–41). In most cases studied to date, this initial cleavage is
essential for the intramembrane cut to occur. Thus, substrate
specificity of PS/g-secretase and SPP may be determined as
much by this priming cleavage as the respective substrate
sequence itself.
One of the most striking differences between PSs and SPP is
the apparent opposite positioning of the active site motif-
containing transmembrane regions within the plane of the
membrane (31,42). This positioning correlates with the opposite
orientation of the respective substrates. PS substrates have a
type I membrane topology with their COOH-termini facing the
cytosol, whereas SPP substrates have a type II topology with
their NH2-termini facing the cytosol. Thus, it appears that
related proteases with inversed proteolytic domains evolved for
the cleavage of membrane spanning peptides of different
topologies.
Despite the common features, there are major differences
between PSs and SPP. The reconstitution of human SPP in the
yeast Saccharomyces cerevisiae, which does not express an
orthologous ‘signal peptide peptidase’, suggested that human
SPP does not require additional proteins for activity (31).
In contrast, PSs appear to require at least three additional pro-
tein partners for activity. PSs undergo endoproteolytic activa-
tion, which may depend on these components and, together
Table 1. PS/g-secretase substrates
Substrate Relevant fragments Functions
APP Ab and cytoplasmic
domain (AID, AICD)
AID: Nuclear signaling in
complex with TIF; regulation
of ER calcium stores. Ab:
physiologic role unknown,
pathologic role in AD
APLP1 Cytoplasmic domain Nuclear signaling?
APLP2 Cytoplasmic domain Nuclear signaling?
Notch 1-4 Cytoplasmic domain
(NICD)
Nuclear signaling in complex
with transcription factor.
Erb-B4 Cytoplasmic domain
(S80)
Signaling by translocation of
kinase domain to nucleus.
E-Cadherin Cytoplasmic domain Regulation of adherens junction?
LRP Cytoplasmic domain Unknown
Delta-1 and
Jagged
Cytoplasmic domain Antagonist role in Notch signaling?
Nectin-1a Cytoplasmic domain Unknown
CD44 Cytoplasmic domain Signaling?
Table 2. SPP substrates
Substrate Relevant fragments Functions
Signal peptides
of human MHC
class I molecules
HLA-E epitope Immune surveillance
Signal peptide of
prolactin
Cytoplasmic portion
of signal peptide
Calmodulin signaling?
(enhancer of prolactin
secretion?)
Hepatitis C virus
polyprotein
HCV core protein Subunit of virus capsid
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with these additional proteins, forms an active g-secretase
complex. Such activation and complex formation may provide
means of control of the protease’s intramembrane-cleaving
activity, and regulate substrate delivery and/or trafficking to the
intracellular site of action. In the case of SPP, there is no
indication for endoproteolysis or any another activation step.
Nevertheless, its activity is almost certainly regulated in some
fashion; SPP does not appear to randomly attack membrane
proteins in the ER. Rather than the protease activity, properties of
the substratesmay account for controlled proteolysis bySPP (33).
OTHER HOMOLOGS
Shortly after the identification of human PSs, homologs were
recognized in plants, invertebrates and vertebrates. Some of the
close homologs such as those found in C. elegans and
Drosophila, have been extensively studied and shown to
function as aspartic I-CLiPs in high molecular weight
complexes like the human PSs (reviewed in 2). More recently,
in addition to SPP, a number of other potential aspartic I-CLiPs
with less obvious homology to PSs have been recognized
by database searching (Table 3) (31,35,43). These proteins
have no identified function and have been referred to by
various names. Herein, they will be referred to as presenilin
homologs/signal peptide peptidase-like proteases (PSH/SPPL),
although with future functional assignment we propose that
they would be renamed to more accurately reflect their
function. In humans, four PSH/SPPLs with unknown functions
have been recognized. PSH/SPPLs are predicted to be integral
membrane proteins with multiple membrane spanning regions,
and to contain both the conserved transmembrane aspartates in
the motifs YD and LGhGD, and the PAL motif near the
COOH-terminus. In addition, several members of the family
contain a protease-associated domain near their NH2-terminus.
When found in some classic protease, this domain is involved
in substrate binding (44).
MODELS OF CLEAVAGE
Although much has been learned about intramembrane
cleavage, the exact manner in which these reactions occur
remains a mystery. The conservation of putative active site
motifs between I-CLiPs and classic proteases indicates that the
catalytic mechanism of I-CLiPs most likely involves hydro-
lysis. If this is the case, then water must somehow gain entry
into the active site of these proteases and the labile bonds
within the substrate’s transmembrane region must at some point
be exposed to an activated water molecule. In Figure 1,
Table 3. PS and PSH family members
Protein Chr.
locus
Protein
length
Asp 1 Asp 2 PAL Endoproteolyzed PA domain Function
PS1 14 467 YDLC LGLGDFI LPALPI Yes No g-Secretase
PS2 1 446 YDLV LGLGDFI LPALPI Yes No g-Secretase
SPP 20 377 YDVF LGLGDVV QPALLY No No Signal peptide peptidase
SPPL3/PSH1 12 385 YDVF LGIGDIV QPALLY ? No Unknown
SPPL2a/PSH5 15 409 YDVF LGFGDII QPALLY ? Yes Unknown
SPPL2b/PSH4 19 564 YDIF LGFGDIL QPALLY No Yes Unknown
SPPL2c/PSH2 17 684 FDVF LGFGDIV QPALLY No Yes Unknown/pseudogene?
Figure 1. Possible models of cleavage by an I-CLiP. Several models are presented that could permit water access to the active site. (A) An I-CLiP may form a
shallow or deep hydrophilic pocket in the membrane. This would allow access of water to the catalytic residues (indicated by the two stars). The pocket may form
upon a conformational change induced by binding of the substrate. (B) Two units of an I-CLiP may act as a dimer to carry out the cleavage. In this case, substrate
binding to one I-CLiP unit may induce a conformational change and the formation of a pore containing a merged active site.
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theoretical models that might fulfill these two requirements are
shown. The first model (Fig. 1A) is one in which the multiple
transmembrane regions of the protease form a hydrophilic
pocket or groove at one face of the membrane. This model is
compatible with I-CLiP cleavage sites that lie close to the
cytosolic or lumenal face of the membrane, such as those that
release the cytoplasmic tail of APP and Notch. However,
cleavage events such as those that generate Ab and appear to
occur in the middle of the membrane, might either require
some perpendicular movement of the substrate or protease
within the membrane, or possibly a very deep hydrophilic
pocket. A variant of this model might be that the transmem-
brane regions of the I-CLiP adopt a horseshoe like structure.
Upon association of the substrate to the active site, a channel or
pore might be formed allowing access of water to the site of
hydrolysis. Such a model might require distinct initial binding
sites of the substrate followed by transfer into the active site.
Another model (Fig. 1B), that might be suggested by recent
data showing that both PSs and SPP may form dimers in vivo,
is one in which the initial binding of substrate occurs in one
active site. This binding could then induce a conformational
shift resulting in the merger of the two subunits that together
form a pore like structure. Alternatively, a distinct substrate-
binding site on one subunit could result in presentation of
the substrate to the active site of the other subunit. Additional
models of cleavage that combine various aspects of these
models are possible. Finally, it is possible that a given I-CLiP
may utilize a novel mechanism of catalysis that is compatible
with cleavage of a peptide bond in a lipid environment.
CONCLUSIONS
The aspartic I-CLiPs represent a newly recognized and
biomedically important family of proteases. Intense study of
PSs and g-secretase has led to the development of potent
inhibitors of g-secretase activity several of which have entered
phase I trials in humans. Distinct g-secretase inhibitors have
overlapping activity against SPP (38), it is highly expected that
many of those compounds may also target the other PSH/
SPPLs. Thus, the specificity of g-secretase inhibitors must be
questioned. Because of the potential clinical significance of
g-secretase inhibitors, there is urgent need to increase our
understanding of these proteins. Even with the experience
gained by studying PSs and SPP, this will remain a difficult
task. To date, there is no easily identifiable strategy that is
assured of identifying function or substrate for these novel
aspartic I-CLiPs. Nevertheless, because inhibitor specificity
may prove instrumental, if inhibitors of aspartic I-CLiPs
prove to be of therapeutic utility, this assignment of function
and development of activity assays for each is extremely
important.
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